Toronto - Delayed Quote ? CAD Medexus Pharmaceuticals Inc. (MDP.TO) Follow Compare 2.4600 -0.0400 (-1.60%) At close: October 22 at 3:59 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 19, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareholders elected all nominees listed in Medexus's management information circular dated August 7, 2024 as directors through the next annual meeting. Shareholders also voted in favor of the appointment of PricewaterhouseCoopers LLP as the company's auditors.Detailed voting results for the election of di Newsfile ? last month MEDXF Medexus Provides Update on Treosulfan NDA Review Process and Extended PDUFA Goal Date Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 16, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) has been informed by medac, licensor of Medexus's commercialization rights to treosulfan, that the US Food and Drug Administration has extended the review period for the New Drug Application for treosulfan by three months. The FDA has set a new PDUFA target action date of January 30, 2025.The FDA notified medac that the Agency requires additional time ... Newsfile ? last month MEDXF Some May Be Optimistic About Medexus Pharmaceuticals' (TSE:MDP) Earnings Medexus Pharmaceuticals Inc.'s ( TSE:MDP ) stock was strong despite it releasing a soft earnings report last week. We... Simply Wall St. ? 2 months ago MEDXF Medexus Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next Medexus Pharmaceuticals Inc. ( TSE:MDP ) just released its first-quarter report and things are looking bullish. It was... Simply Wall St. ? 2 months ago MEDXF Medexus Announces Strong Fiscal Q1 2025 Results Fiscal Q1 2025 revenue of $27.3 million, net income of $2.0 million, operating income of $4.0 million, and Adjusted EBITDA* of $6.1 millionManagement to host conference call at 8:00 AM Eastern time on Thursday, August 8, 2024Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 7, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's first fiscal quarter ended June 30, ... Newsfile ? 2 months ago MEDXF Medexus Schedules First Fiscal Quarter 2025 Conference Call Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - July 30, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, August 8, 2024 to discuss Medexus's results for its first fiscal quarter ended June 30, 2024. Medexus expects to file its financial statements and MD&A after markets close on August 7, 2024.To participate in the call, please dial the following numbers:888-506-0062 (toll-free) for Canadian ... Newsfile ? 2 months ago MEDXF Medexus Generates Record Revenue of US$113.1 Million in Fiscal Year 2024 FDA has Accepted for Review the Treosulfan NDAManagement to host conference call at 8:00 AM Eastern time on Wednesday, June 26, 2024Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 25, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's fourth fiscal quarter and fiscal year ended March 31, 2024 (the company's fiscal Q4 2024 and fiscal year 2024). All dollar ... Newsfile ? 3 months ago MEDXF Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2024 Conference Call Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 18, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Wednesday, June 26, 2024 to discuss Medexus's results for its fourth fiscal quarter and fiscal year ended March 31, 2024. Medexus expects to file its financial statements and MD&A after markets close on June 25, 2024.To participate in the call, please dial the following numbers:888-506-0062 ... Newsfile ? 4 months ago MEDXF FDA Accepts for Review Treosulfan NDA Resubmission Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 6, 2024) - On Thursday, June 6, 2024, Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) was informed by medac, licensor of Medexus's commercialization rights to treosulfan, that the US Food and Drug Administration has accepted for review medac's April 2024 resubmission of the New Drug Application for treosulfan. Medexus expects that the FDA will complete its review of the treosulfan NDA and issue a decision by October ... Newsfile ? 4 months ago MEDXF With A Return On Equity Of 20%, Has Medexus Pharmaceuticals Inc.'s (TSE:MDP) Management Done Well? While some investors are already well versed in financial metrics (hat tip), this article is for those who would like... Simply Wall St. ? 5 months ago MEDXF Medexus Concludes Metoject Litigation, Patent No Longer in Effect in Canada Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - May 1, 2024) - Following a trial in January 2023, Canada's Federal Court has issued a judgment declining to uphold the Canadian patent for Metoject?. Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) and medac, licensor of Medexus's commercialization rights to Metoject?, have elected not to appeal the trial court decision. Medexus and medac initiated the litigation in August 2020 in response to the "at-risk" launch of a generic ... Newsfile ? 5 months ago MEDXF Medexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 2, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference from April 16 to 17, 2024.Event: 2024 Bloom Burton & Co. Healthcare Investor ConferenceDate: April 16-17, 2024Location: Toronto, OntarioMedexus Presentation: Wednesday, April 17 at 1:30 PM Eastern timeKen d'Entremont, Medexus's Chief Executive Newsfile ? 6 months ago MEDXF FDA Approves Medexus's Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients Expanded indication includes patients under 12 years of age, based on Phase 3/4 data demonstrating safety and efficacy in previously treated patients in this age group Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - March 26, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced that the US Food and Drug Administration (FDA) recently approved Medexus's supplemental Biologics License Application (sBLA) for IXINITY? [coagulation factor IX (recombinant)] for the on-dem Newsfile ? 6 months ago MEDXF Medexus Pharmaceuticals Inc. (TSE:MDP) Analysts Just Slashed Next Year's Estimates The analysts covering Medexus Pharmaceuticals Inc. ( TSE:MDP ) delivered a dose of negativity to shareholders today, by... Simply Wall St. ? 8 months ago MEDXF Medexus Pharmaceuticals Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next One of the biggest stories of last week was how Medexus Pharmaceuticals Inc. ( TSE:MDP ) shares plunged 24% in the week... Simply Wall St. ? 8 months ago MEDXF Medexus Announces Fiscal Q3 2024 Results Fiscal Q3 2024 revenue of $25.2 million, Operating income of $1.6 million, and Adjusted EBITDA* of $3.2 millionManagement to host conference call at 8:00 AM Eastern time on Thursday, February 8, 2024Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 7, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's third fiscal quarter ended December 31, 2023 (the company's fiscal Q3 .. Newsfile ? 8 months ago MEDXF Medexus Schedules Third Fiscal Quarter 2024 Conference Call Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 30, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, February 8, 2024 to discuss Medexus's results for its third fiscal quarter ended December 31, 2023. Medexus expects to file its financial statements and MD&A after markets close on February 7, 2024.To participate in the call, please dial the following numbers:888-506-0062 (toll-free) for Canadian ... Newsfile ? 8 months ago MEDXF Health Canada Accepts for Review Medexus's New Drug Submission for Topical Terbinafine Topical terbinafine has been widely used in other markets to treat fungal nail infectionsIf and when approved, the product will enter the topical fungicides market that is estimated to be C$88 million on an annual basis*Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 8, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced that Health Canada recently accepted for review Medexus's new drug submission, or NDS, for terbinafine hydrochloride nail lacquer to trea Newsfile ? 9 months ago MEDXF Boasting A 23% Return On Equity, Is Medexus Pharmaceuticals Inc. (TSE:MDP) A Top Quality Stock? While some investors are already well versed in financial metrics (hat tip), this article is for those who would like... Simply Wall St. ? 10 months ago MEDXF Medexus Announces Strong Fiscal Q2 2024 Results, Including Quarterly Revenue of US$30.3 Million Fiscal Q2 2024 revenue reflects a 9.4% increase over fiscal Q2 2023, demonstrating strong revenue growth and continued overall performanceManagement to host conference call at 8:00 AM Eastern time on Thursday, November 9, 2023Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 8, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's second fiscal quarter ended September 30, 202 Newsfile ? 11 months ago MEDXF Performance Overview Trailing total returns as of 10/22/2024, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index Return MDP.TO S&P/TSX Composite index YTD -0.40% +17.93% 1-Year +11.31% +29.30% 3-Year -27.00% +16.52%
